Kaminski et al. introduced cam1615TEM8, a novel TriKE molecule that activates NK cells with IL-15 and targets TEM8-positive tumor and stromal cells, offering a multifaceted approach to solid tumor therapy [172]. This evidence concerns the gene IL15 and neoplasm.